Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Source: Article title.
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Systematic review · Nutrition Reviews · 2025
Original publication title
Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
© The Author(s) 2025. Published by Oxford University Press on behalf of the International Life Sciences Institute.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Source: ObjectiveAbstract: Context
Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.
Source: ContextAbstract: Data Sources
We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.
Source: Data SourcesAbstract: Data Extraction
Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.
Source: Data ExtractionAbstract: Data Analysis
Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, −23.50 dB/m; 95% CI, −81.72 to 34.72; 3 RCTs) and LSM (MD, −0.65 kPa; 95% CI, −1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, −0.31; 95% CI, −0.62 to −0.01; 15 RCTs).
Alanine aminotransferase (ALT) (MD, −4.98 IU/L; 95% CI, −8.28 to −1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, −3.33 IU/L; 95% CI, −6.25 to −0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, −5.14 IU/L; −6.40; −3.88; 11 RCTs), triglycerides (MD, −7.59 mg/dL; 95% CI, −15.09 to −0.81), and insulin (MD −0.79 μIU/L; 95% CI, −1.36 to −0.21) were significantly reduced in the patients with vitamin D supplementation.
Source: Data AnalysisAbstract: Systematic Review Registration
PROSPERO registration No. CRD42022370312
Source: Systematic Review RegistrationAbstract: Conclusion
Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D: supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.
Source: ConclusionAuthors’ abstract
Abstract
Context
Vitamin D deficiency is highly prevalent in chronic liver disease. Although international societies recommend vitamin D supplementation in cases of proven deficiency, the impact of vitamin D on chronic liver disease remains uncertain.
Objective
Our aim was to evaluate the effects of vitamin D supplementation in patients with chronic liver disease by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Data Sources
We systematically searched PubMed, EMBASE and the Cochrane Library on July 2, 2024.
Data Extraction
Our primary outcomes involved survival, controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and effects on changes in liver enzymes. Secondary outcomes included lipid profile and homeostasis model assessment of insulin resistance (HOMA-IR), among others. The pooled risk ratio (RR), mean difference (MD), and corresponding 95% CIs were calculated using the random-effects model.
Data Analysis
Forty-six RCTs were included, comprising 4084 patients. When we compared the vitamin D group with the control, the RR for overall survival was 1.14 (95% CI, 0.85-1.54; 4 RCTs) at 6 months and 0.99 (95% CI, 0.83-1.17; 4 RCTs) at the 12-month follow-up. Vitamin D supplementation did not result in a lower CAP (MD, −23.50 dB/m; 95% CI, −81.72 to 34.72; 3 RCTs) and LSM (MD, −0.65 kPa; 95% CI, −1.98 to 0.68; 3 RCTs). A significant reduction in HOMA-IR was observed in the vitamin D group (MD, −0.31; 95% CI, −0.62 to −0.01; 15 RCTs).
Alanine aminotransferase (ALT) (MD, −4.98 IU/L; 95% CI, −8.28 to −1.68; 24 RCTs), aspartate aminotransferase (AST) (MD, −3.33 IU/L; 95% CI, −6.25 to −0.40; 23 RCTs), gamma-glutamyl transferase (GGT) (MD, −5.14 IU/L; −6.40; −3.88; 11 RCTs), triglycerides (MD, −7.59 mg/dL; 95% CI, −15.09 to −0.81), and insulin (MD −0.79 μIU/L; 95% CI, −1.36 to −0.21) were significantly reduced in the patients with vitamin D supplementation.
Conclusion
Our results showed significantly reduced ALT, AST, GGT, triglycerides, insulin, and HOMA-IR in the vitamin D: supplemented group; however, the effect was modest. In addition, there were no differences in survival, CAP, or LSM. Further RCTs with adequate power are warranted to clarify the results.
Systematic Review Registration
PROSPERO registration No. CRD42022370312
Publication and source details
Original title: Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Petrana Martinekova; Mahmoud Obeidat; Mihaela Topala; Szilárd Váncsa; Dániel Sándor Veres; Ádám Zolcsák; Miheller Pál; László Földvári-Nagy; Peter Banovcin; Bálint Erőss; Péter Hegyi; Krisztina Hagymasi
Nutrition Reviews · 2025
Corresponding Author: Krisztina Hagymasi, Department of Surgery, Transplantation, and Gastroenterology; Semmelweis University, H-1082 Budapest, Üllői út 78, Hungary (hagymasi.krisztina@semmelweis.hu).© The Author(s) 2025. Published by Oxford University Press on behalf of the International Life Sciences Institute.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:54:16.950174+00:00
DOI: 10.1093/nutrit/nuaf117 · PMC12512233